On May 19, 2022 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that its President and Chief Executive Officer, Rodney Varner, will be providing a virtual overview of the Company’s gene therapies for cancer and diabetes to investors at the following conference in May 2022 (Press release, Genprex, MAY 19, 2022, View Source [SID1234614899]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: H.C. Wainwright Global Investment Conference (Virtual and In-Person)
Conference Dates: May 23-26, 2022
Virtual Presentation Date: Available on-demand within the virtual platform for all delegates beginning May 24 at 7 a.m. ET
Presenter: Rodney Varner, Genprex’s President and Chief Executive Officer

Mr. Varner will deliver an overview of the Company’s pioneering gene therapies for cancer and diabetes and will be available for virtual one-on-one meetings with investors through the H.C. Wainwright conference platform